Direct-to-Patient Expansion Science 37’s Direct-to-Patient Site model enables sponsors to broaden patient access, improve retention, and achieve more representative enrollment, presenting a sales opportunity to healthcare brands seeking decentralized trial capabilities and diverse populations.

FDA Inspections & Compliance With a track record of successful FDA inspections and No Action Indicated classifications, Science 37 offers a low compliance risk profile for sponsors pursuing rigorous regulatory standards across multi-state trials.

Clinical Throughput Leadership Proven performance metrics such as high completion rates and substantial single-site enrollment indicate strong operational efficiency, enabling quick study start-ups and reliable timelines for sponsors.

Strategic Partnerships Recent collaborations with PatientsLikeMe and Catalent highlight a strategy of expanding access and capabilities, suggesting opportunities for co-development, channel partnerships, or integrated trial solutions.

Growth & Talent Momentum Executive appointments and recognition in industry awards signal organizational growth and strategic investments, creating openings for senior strategic conversations around transformation, scaling, and long-term partnerships.